

Title (en)

COMPOSITIONS AND METHODS FOR SYSTEMIC INHIBITION OF CARTILAGE DEGRADATION

Title (de)

ZUSAMMENSETZUNGEN UND VERFAHREN FÜR DIE SYSTEMISCHE UNTERDRÜCKUNG VON KNORPELABBAU

Title (fr)

COMPOSITIONS ET METHODES D'INHIBITION SYSTEMIQUE DE LA DEGRADATION DU CARTILAGE

Publication

**EP 1496835 A4 20061018 (EN)**

Application

**EP 03708941 A 20030131**

Priority

- US 0303175 W 20030131
- US 35355202 P 20020201

Abstract (en)

[origin: WO03063799A2] Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

[origin: WO03063799A2] Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

IPC 8 full level

**A61K 9/14** (2006.01); **A61K 9/50** (2006.01); **A61K 38/00** (2006.01); **A61K 38/22** (2006.01); **A61K 38/27** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61K 47/34** (2006.01); **A61K 47/36** (2006.01); **A61K 47/42** (2006.01); **A61K 47/48** (2006.01); **A61P 19/02** (2006.01); **A61P 19/04** (2006.01); **A61P 29/00** (2006.01); **A61P 41/00** (2006.01)

CPC (source: EP KR)

**A61K 38/20** (2013.01 - KR); **A61K 39/395** (2013.01 - KR); **A61K 47/6849** (2017.07 - EP); **A61K 47/6929** (2017.07 - EP); **A61K 47/6935** (2017.07 - EP); **A61K 47/6937** (2017.07 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/04** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 41/00** (2017.12 - EP); **B82Y 5/00** (2013.01 - EP)

Citation (search report)

- [X] WO 0025745 A2 20000511 - OMEROS MED SYS INC [US], et al
- [PX] WO 02096367 A2 20021205 - TARGESOME INC [US]
- See references of WO 03063799A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

DOCDB simple family (publication)

**WO 03063799 A2 20030807**; **WO 03063799 A3 20041104**; AU 2003212898 B2 20081002; CA 2474645 A1 20030807; CA 2474645 C 20110809; CN 1697647 A 20051116; EP 1496835 A2 20050119; EP 1496835 A4 20061018; JP 2005519917 A 20050707; KR 20040094413 A 20041109; MX PA04007124 A 20041029

DOCDB simple family (application)

**US 0303175 W 20030131**; AU 2003212898 A 20030131; CA 2474645 A 20030131; CN 03803136 A 20030131; EP 03708941 A 20030131; JP 2003563495 A 20030131; KR 20047011603 A 20030131; MX PA04007124 A 20030131